MeSH tree: D23.050.705
In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the vicinity of a tumor, ...
Feb 16, 2026
0
0
A team of scientists has uncovered a critical mechanism that could pave the way for safer and more effective obesity treatments. The findings, published in Nature Communications, shed light on how leptin, a hormone that regulates ...
Feb 6, 2026
0
22
A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma (PDAC) compared to measuring ...
Jan 28, 2026
0
0
To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most genetic medicine uses viruses or double-stranded DNA to deliver genetic information to target cells. ...
Dec 13, 2025
0
0
Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic tools. While the traditional staging systems, such as the TNM classification, focus on anatomical ...
Dec 13, 2025
0
0
USC biomedical engineers have found a way to make a solid tumor paint a target on its own back in order to train the body's immune system to find and destroy it.
Dec 11, 2025
0
37
No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating them with chemotherapy or radiation—which have undesirable side effects—what if we could train ...
Dec 10, 2025
0
0
HLA compatibility is considered the key criterion for selecting donors for allo-HSCT. DKMS study data presented at the DGHO Annual Meeting 2025 in Cologne indicate the biological age of donors has a greater influence on transplant ...
Nov 19, 2025
0
0
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, ...
Oct 22, 2025
0
0
An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, that could be a new treatment for a group of lung cancer patients who have few options today.
Oct 17, 2025
0
5
